Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDBiomarin Pharmaceutical Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2026 | 13 | $0.53 | $0.85 | $0.69 |
| Q2 2026 | 9 | $0.62 | $0.91 | $0.77 |
| Q3 2026 | 9 | $0.98 | $1.22 | $1.12 |
| Q4 2026 | 7 | $1.27 | $1.48 | $1.38 |
| Q1 2027 | 3 | $1.10 | $1.29 | $1.21 |
| Q2 2027 | 3 | $1.14 | $1.34 | $1.25 |
| Q3 2027 | 4 | $1.19 | $1.40 | $1.30 |
| Q4 2027 | 3 | $1.25 | $1.47 | $1.37 |
Biomarin Pharmaceutical Inc. Earnings Date And Information
Biomarin Pharmaceutical Inc. last posted its earnings results on Monday, May 4th, 2026. The company reported $0.55 earnings per share for the quarter, missing analysts' consensus estimates of $0.94 by $0.39. The company had revenue of 766.21 M for the quarter and had revenue of 3.22 B for the year. Biomarin Pharmaceutical Inc. has generated $2 earnings per share over the last year ($1.8 diluted earnings per share) and currently has a price-to-earnings ratio of 38.36. Biomarin Pharmaceutical Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is N/A based on prior year's report dates.
Biomarin Pharmaceutical Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 05/05/2026 | Q1 2026 | N/A | $0.55 | N/A | $752.53 M | $766.21 M |
| 02/26/2026 | Q4 2025 | N/A | -$0.24 | N/A | $833.73 M | $874.57 M |
| 10/28/2025 | Q3 2025 | N/A | -$0.16 | N/A | $777.48 M | $776.13 M |
| 08/05/2025 | Q2 2025 | N/A | $1.25 | N/A | $761.95 M | $825.41 M |
| 05/02/2025 | Q1 2025 | N/A | $0.97 | N/A | $738.66 M | $745.15 M |
| 02/24/2025 | Q4 2024 | N/A | $0.66 | N/A | $712.30 M | $747.31 M |
| 10/31/2024 | Q3 2024 | N/A | $0.57 | N/A | $703.43 M | $745.74 M |
| 08/05/2024 | Q2 2024 | $0.36 | $0.56 | 0.2 | $663.98 M | $712.03 M |
| 04/26/2024 | Q1 2024 | N/A | $0.47 | N/A | $651.83 M | $648.83 M |
| 02/26/2024 | Q4 2023 | N/A | $0.11 | N/A | N/A | $646.21 M |
| 11/02/2023 | Q3 2023 | N/A | $0.21 | N/A | $638.82 M | $581.33 M |
| 08/02/2023 | Q2 2023 | N/A | $0.30 | N/A | $603.84 M | $595.28 M |
| 04/28/2023 | Q1 2023 | N/A | $0.27 | N/A | N/A | $596.42 M |
| 02/27/2023 | Q4 2022 | -$0.07 | -$0.00 | 0.07 | N/A | $537.54 M |
| 10/28/2022 | Q3 2022 | N/A | -$0.04 | N/A | $537.62 M | $505.34 M |
| 08/04/2022 | Q2 2022 | N/A | $0.15 | N/A | $518.45 M | $533.80 M |
| 04/29/2022 | Q1 2022 | N/A | $0.63 | N/A | N/A | $519.36 M |
| 02/25/2022 | Q4 2021 | N/A | -$0.32 | N/A | N/A | $449.81 M |
| 10/29/2021 | Q3 2021 | N/A | -$0.20 | N/A | $442.38 M | $408.74 M |
| 07/30/2021 | Q2 2021 | N/A | $0.07 | N/A | $435.30 M | $501.69 M |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Biomarin Pharmaceutical Inc. Earnings: FAQ's
The conference call for Biomarin Pharmaceutical Inc.'s latest earnings report can be listened to online.
The conference call transcript for Biomarin Pharmaceutical Inc.'s latest earnings report can be read online.
Biomarin Pharmaceutical Inc. (:BMRN) has a recorded annual revenue of $3.22 B.
Biomarin Pharmaceutical Inc. (:BMRN) has a recorded net income of $348.90 M.Biomarin Pharmaceutical Inc. has generated $1.82 earnings per share over the last four quarters.
Biomarin Pharmaceutical Inc. (:BMRN) has a price-to-earnings ratio of 38.36 and price/earnings-to-growth ratio is -0.78.